Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden · Delayed Price · Currency is SEK 325.00
+1.00 (0.31%)
Oct 28, 2025, 1:59 PM CET
Swedish Orphan Biovitrum AB Employees
Swedish Orphan Biovitrum AB had 1,806 employees as of December 31, 2024. The number of employees increased by 66 or 3.79% compared to the previous year.
Employees
1,806
Change (1Y)
66
Growth (1Y)
3.79%
Revenue / Employee
14.74M SEK
Profits / Employee
6.88K SEK
Market Cap
111.67B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,806 | 66 | 3.79% |
| Dec 31, 2023 | 1,740 | 184 | 11.83% |
| Dec 31, 2022 | 1,556 | -3 | -0.19% |
| Dec 31, 2021 | 1,559 | 50 | 3.31% |
| Dec 31, 2020 | 1,509 | 174 | 13.03% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Medicover AB | 47,256 |
| Getinge AB | 11,791 |
| Nolato AB | 5,837 |
| Elekta AB | 4,556 |
| Asker Healthcare Group AB | 4,030 |
| AddLife AB | 2,181 |
| Sectra AB | 1,296 |
| Vimian Group AB | 1,200 |
Swedish Orphan Biovitrum AB News
- 4 days ago - Swedish Orphan Biovitrum AB (BIOVF) Q3 2025 Earnings Call Highlights: Strong Growth and ... - GuruFocus
- 4 days ago - Q3 2025 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript - GuruFocus
- 7 days ago - Swedish Orphan Biovitrum AB (publ) (SWOBY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Swedish Orphan Biovitrum AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 8 days ago - Sobi Q3 Adj. EBITA Rises - Nasdaq
- 8 days ago - Sobi raises 2025 financial forecast after Q3 revenue jumps 21% - Seeking Alpha
- 5 weeks ago - KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs - Seeking Alpha
- 5 weeks ago - Ionis Pharmaceuticals And Sobi Say EU Approves TRYNGOLZA For Familial Chylomicronemia Syndrome - Nasdaq